TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6097665

Group type: EXPERIMENTAL
Intervention: Enalapril maleate (40 mg) in fasting state
Number of subjects: 12

Group type: COMPARATOR
Intervention: Enalapril maleate (40 mg) with a standard breakfast
Number of subjects: 12
Study: 31729825

Group type: EXPERIMENTAL
Intervention: Baerveldt glaucoma implant (BGI)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Trabeculectomy (TE)
Number of subjects: 119
Study: 31851542

Group type: EXPERIMENTAL
Intervention: TeamSTEPPS team training (6 hours) and implementation of teamwork tools and strategies (12 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29908803

Group type: EXPERIMENTAL
Intervention: Fixed milk allowance (FIX) of 6 to 8 L/d from day 1 after birth
Number of subjects: 1264

Group type: COMPARATOR
Intervention: Slowly increasing milk allowance (INC) starting from 4 to 5 L/d to reach 6 to 8 L/d over 7 to 14 days
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Fixed milk allowance (FIX)
Number of subjects: 1264

Group type: COMPARATOR
Intervention: Both FIX and INC groups
Number of subjects: 1264
Study: 27931254

Group type: EXPERIMENTAL
Intervention: STAK-D intervention website and wrist-worn activity monitor for 6 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: STAK-D intervention
Number of subjects: 50
Study: 24725515

Group type: EXPERIMENTAL
Intervention: Real-time feedback using wireless technology
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Real-time feedback using wireless technology (post-implementation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 22652379

Group type: EXPERIMENTAL
Intervention: Tomato paste supplementation (70 g containing 33.3 mg of lycopene)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no tomato paste added to regular diet)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tomato paste supplementation
Number of subjects: 19
Study: 20116300

Group type: EXPERIMENTAL
Intervention: First RCT (N = 244)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Second RCT (N = 101)
Number of subjects: 345
Study: 18544158

Group type: EXPERIMENTAL
Intervention: LIGHT (40% peak oxygen consumption, VO2peak)
Number of subjects: 46

Group type: COMPARATOR
Intervention: MODERATE (60% VO2peak)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-exercise control
Number of subjects: 46
Study: 16115357

Group type: EXPERIMENTAL
Intervention: 3 mg elemental Cu/d as CuSO4
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 6 mg elemental Cu/d as CuSO4
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0 mg elemental Cu/d (control)
Number of subjects: 16
Study: 12423712

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 129

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 129

Group type: COMPARATOR
Intervention: Irbesartan vs Atenolol
Number of subjects: 129
Study: 10524892

Group type: EXPERIMENTAL
Intervention: Orchiectomy alone
Number of subjects: 184

Group type: COMPARATOR
Intervention: Orchiectomy plus mitomycin C
Number of subjects: 184
Study: 7591024

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Lifestyle modification education control
Number of subjects: 127
Study: 1722167

Group type: EXPERIMENTAL
Intervention: Finasteride (5 alpha-reductase inhibitor); varying doses administered to men with benign prostatic hyperplasia.
Number of subjects: 0
Study: 6638144

Group type: EXPERIMENTAL
Intervention: Creative activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imitation activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intuitive types
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sensing types
Number of subjects: 0
Study: 28925286

Group type: EXPERIMENTAL
Intervention: High dosage VFE (four times)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Traditional dosage VFE (twice)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low dosage VFE (once)
Number of subjects: 28
Study: 30418882

Group type: EXPERIMENTAL
Intervention: Motorized Ankle Stretcher (MAS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Stretching board (Control)
Number of subjects: 16
Study: 26903058

Group type: EXPERIMENTAL
Intervention: BTX‐A injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 80
Study: 23828145

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (45 mg/day) and risedronate (2.5 mg/day or 17.5 mg/week)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Risedronate alone (2.5 mg/day or 17.5 mg/week)
Number of subjects: 910
Study: 19789648

Group type: EXPERIMENTAL
Intervention: Community-based delivery system
Number of subjects: 964

Group type: COMPARATOR
Intervention: Facility-based delivery system
Number of subjects: 964
Study: 15208869

Group type: EXPERIMENTAL
Intervention: Low-energy helium-neon laser exposure and decimeter electromagnetic radiation (DMEM)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: DMEM-therapy
Number of subjects: 58
Study: 11290635

Group type: EXPERIMENTAL
Intervention: Home chemotherapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 87
Study: 9327116

Group type: EXPERIMENTAL
Intervention: Air Pocket (AP) rebreather
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short Term Air Supply System (STASS) mini SCUBA set
Number of subjects: 0
Study: 8098951

Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia (droperidol and fentanyl)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 100
Study: 3307061

Group type: COMPARATOR
Intervention: Antilymphoblast globulin (ALG), azathioprine (AZA), and prednisone (P)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Cyclosporine (CsA) plus prednisone
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Combination of azathioprine, cyclosporine, and prednisone (+/- ALG)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Nondiabetic patients
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Older patients (>45 years)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Heavier patients (>70 kg)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Recipients of cadaveric allografts
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Patients hospitalized for infections
Number of subjects: 173
Study: 30489432

Group type: EXPERIMENTAL
Intervention: High-dose calfactant (8.0 mg/ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-dose calfactant (0.8 mg/ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29523450

Group type: EXPERIMENTAL
Intervention: Additional early dose of measles vaccine (MV) 4 weeks after the third dose of DTP-containing Pentavalent vaccine and standard MV at 9 months
Number of subjects: 4496

Group type: COMPARATOR
Intervention: Standard measles vaccine (MV) at 9 months (control)
Number of subjects: 4496

Group type: EXPERIMENTAL
Intervention: Additional early dose of measles vaccine (MV) in children not exposed to an OPV campaign after enrolment
Number of subjects: 4496
Study: 26498324

Group type: EXPERIMENTAL
Intervention: Trastuzumab therapy
Number of subjects: 50
Study: 24683472

Group type: EXPERIMENTAL
Intervention: Elevated plasma levels of β2‐microglobulin (B2M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated plasma levels of fibroblast growth factor 23 (FGF23)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated plasma levels of interleukin‐8 (IL‐8)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated plasma levels of IL‐18
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated plasma levels of IL‐2 receptor alpha (IL‐2 RA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated plasma levels of tumour necrosis factor receptor type I
Number of subjects: 0
Study: 22078632

Group type: EXPERIMENTAL
Intervention: 30 mcg ethinyl estradiol (EE)/150 mcg levonorgestrel (LNG)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 20 mcg EE/100 mcg LNG
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Higher dose pill (30 mcg EE/150 mcg LNG)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Lower dose pill (20 mcg EE/100 mcg LNG)
Number of subjects: 109
Study: 19293263

Group type: EXPERIMENTAL
Intervention: dDAVP (0.3 microg/kg) infused over 20 min after a 12-h period of water deprivation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (normoalbuminuric type 1 diabetic patients without DR)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: dDAVP administration
Number of subjects: 45
Study: 17712402

Group type: EXPERIMENTAL
Intervention: Intradermal LIPO-4 vaccine (0.1 ml, 100 microg of each peptide)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intramuscular LIPO-4 vaccine (0.5 ml, 500 microg of each peptide)
Number of subjects: 68
Study: 15256991

Group type: EXPERIMENTAL
Intervention: Topical 0.1% indomethacin solution
Number of subjects: 135

Group type: COMPARATOR
Intervention: Topical 0.1% fluorometholon acetate
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 135
Study: 11280194

Group type: EXPERIMENTAL
Intervention: Oka-derived varicella vaccines administered post-exposure within 3 days of rash onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Varilrix and Varivax II
Number of subjects: 0
Study: 9272811

Group type: EXPERIMENTAL
Intervention: Morphine (10 mg p.o.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rifampin (600 mg/day) with Morphine
Number of subjects: 10
Study: 7946690

Group type: EXPERIMENTAL
Intervention: Iodixanol 270 mg I/ml
Number of subjects: 147

Group type: COMPARATOR
Intervention: Iohexol 300 mg I/ml
Number of subjects: 147
Study: 3364226

Group type: EXPERIMENTAL
Intervention: Disguised alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (alcohol conditioning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol (with expectancy of tonic water)
Number of subjects: 0
Study: 29791437

Group type: EXPERIMENTAL
Intervention: Aquacel dressing
Number of subjects: 230

Group type: COMPARATOR
Intervention: Standard gauze dressing (Control)
Number of subjects: 230
Study: 26580307

Group type: EXPERIMENTAL
Intervention: Light monotherapy (10,000-lux fluorescent white light box for 30 min/d in the early morning plus placebo pill)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Fluoxetine monotherapy (inactive negative ion generator for 30 min/d plus fluoxetine hydrochloride, 20 mg/d)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combination therapy (light and antidepressant)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo (inactive negative ion generator plus placebo pill)
Number of subjects: 122
Study: 26342028

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg) daily for 14 days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg)/isoniazid (300 mg) daily for 14 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Rifampicin (600 mg)/isoniazid (300 mg) after washout
Number of subjects: 34

Group type: COMPARATOR
Intervention: Rifampicin (600 mg) after washout
Number of subjects: 34
Study: 23945074

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham Electroacupuncture (sham EA)
Number of subjects: 40
Study: 20683270

Group type: EXPERIMENTAL
Intervention: EVG/COBI 150 mg/FTC/TDF
Number of subjects: 44

Group type: COMPARATOR
Intervention: FTC + TDF
Number of subjects: 44
Study: 18389731

Group type: EXPERIMENTAL
Intervention: Notched jig
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nontrimmed, square microspecimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Square specimens of 1 mm2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remaining dentin thickness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microspecimen gluing protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crosshead speed
Number of subjects: 0
Study: 16786387

Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (same osteoporosis drug therapy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: New traumatic vertebral body fractures (managed by fixateur interne alone or combination with kyphoplasty)
Number of subjects: 40
Study: 12648731

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11998139

Group type: EXPERIMENTAL
Intervention: Behavior therapy methods for urinary incontinence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9027944

Group type: EXPERIMENTAL
Intervention: Supine position for pelvic and periaortic irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prone position for pelvic and periaortic irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prone position with a belly board
Number of subjects: 0
Study: 1524963

Group type: EXPERIMENTAL
Intervention: Low dosage of pyridostigmine (30 mg three times daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Transdermal hyoscine patches
Number of subjects: 47
Study: 3890160

Group type: EXPERIMENTAL
Intervention: Active treatment with hip joint distension arthrography
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 38
Study: 31766497

Group type: EXPERIMENTAL
Intervention: Structural individual low-FODMAP dietary advice (SILFD)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Brief advice on a commonly recommended diet (BRD)
Number of subjects: 62
Study: 29346228

Group type: EXPERIMENTAL
Intervention: Combined obturator nerve and femoral triangle blockade (OFB)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 74
Study: 26081648

Group type: EXPERIMENTAL
Intervention: Combined model containing all carotenoids and vitamin C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin C only model
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lutein only model
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Model based upon factor analysis
Number of subjects: 30
Study: 24655714

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat (PUFA) intake
Number of subjects: 234

Group type: COMPARATOR
Intervention: Saturated fat
Number of subjects: 234

Group type: COMPARATOR
Intervention: Total fat and carbohydrates
Number of subjects: 234
Study: 22000576

Group type: EXPERIMENTAL
Intervention: Ultrasound-based navigation system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Imageless navigation system with surface registration
Number of subjects: 80
Study: 20185416

Group type: EXPERIMENTAL
Intervention: Medication plus 10 sessions of biofeedback-assisted relaxation training (BART)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standardized medication treatment
Number of subjects: 20
Study: 17919380

Group type: EXPERIMENTAL
Intervention: HTEA (high thoracic epidural anesthesia) with 0.5% lidocaine 3 ‐ 5 ml every two hours for one month
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (routine medication)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: HTEA
Number of subjects: 117
Study: 15616092

Group type: EXPERIMENTAL
Intervention: FTST
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PVCT
Number of subjects: 150

Group type: COMPARATOR
Intervention: LAT
Number of subjects: 150
Study: 12173196

Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg orally every 8 h the day before surgery and 75 mg i.m. every 12 h on the day of surgery)
Number of subjects: 46
Study: 9443711

Group type: EXPERIMENTAL
Intervention: Tiagabine 32 mg daily
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Tiagabine 56 mg daily
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Tiagabine 16 mg daily
Number of subjects: 297
Study: 8536511

Group type: EXPERIMENTAL
Intervention: Endoscopic Papillary Dilation (EPD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (EST)
Number of subjects: 20
Study: 2379255

Group type: EXPERIMENTAL
Intervention: Simultaneous inoculation with DPT and BCG vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: DPT alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 0
Study: 31354

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 30820923

Group type: EXPERIMENTAL
Intervention: Solution based on autonomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solution based on coercion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solution based on reciprocity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salience of patients' need
Number of subjects: 0
Study: 28835400

Group type: EXPERIMENTAL
Intervention: Vertebral angioplasty/stenting plus best medical treatment (BMT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Vertebral angioplasty/stenting plus BMT
Number of subjects: 182
Study: 26424639

Group type: EXPERIMENTAL
Intervention: ACT + Adapted CBSST
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACT alone
Number of subjects: 0
Study: 23796582

Group type: EXPERIMENTAL
Intervention: Fidaxomicin 200 mg b.i.d. for 10 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vancomycin 125 mg q.i.d. for 10 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions (fidaxomicin and vancomycin)
Number of subjects: 100
Study: 21835296

Group type: EXPERIMENTAL
Intervention: Combination antihypertensive therapy (thiazide and potassium-sparing diuretic; thiazide and angiotensin-converting enzyme inhibitor)
Number of subjects: 161585

Group type: COMPARATOR
Intervention: Single-drug initial therapy
Number of subjects: 161585
Study: 19843489

Group type: EXPERIMENTAL
Intervention: Test formulation of valsartan 160 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Reference formulation of valsartan 160 mg
Number of subjects: 38
Study: 16912020

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study: 15212193

Group type: EXPERIMENTAL
Intervention: Drotaverine capsule preparation (20 mg Droxa mite)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Reference tablet preparation
Number of subjects: 23
Study: 10895885

Group type: EXPERIMENTAL
Intervention: Validly cued trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invalidly cued trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutrally cued trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cued conditions (valid and neutral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tests of integrality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative correlated change for frequency
Number of subjects: 0
Study: 9059680

Group type: EXPERIMENTAL
Intervention: Cyclosporine at 3 mg/kg/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Topical betamethasone-17,21-dipropionate
Number of subjects: 41
Study: 7839936

Group type: EXPERIMENTAL
Intervention: Gentle, unilateral breast stimulation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no breast stimulation)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Gentle, unilateral breast stimulation (cross-over trial)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (ex-study)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Gentle, unilateral breast stimulation (in multiparous patients)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (in multiparous patients)
Number of subjects: 300
Study: 3527592

Group type: EXPERIMENTAL
Intervention: Oral 1 g Neomycin plus 0.25 g Metronidazole t.i.d. on the last preoperative day
Number of subjects: 2

Group type: COMPARATOR
Intervention: Intravenous single dose 5 g Mezlocillin plus 0.5 g Metronidazole
Number of subjects: 2
Study: 2840050

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 31772117

Group type: EXPERIMENTAL
Intervention: Cluster randomised trials of health programmes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Research ethics review
Number of subjects: 0
Study: 31217257

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 28830491

Group type: EXPERIMENTAL
Intervention: BioLex®-GLM (600 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26074424

Group type: EXPERIMENTAL
Intervention: Negative condition (write about a heavy drinking event that was negative)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Positive condition (write about a heavy drinking event that was positive)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Neutral condition (write about their first day of college)
Number of subjects: 429
Study: 23333189

Group type: EXPERIMENTAL
Intervention: Three-dimensional quantitative ultrasound (QUS)
Number of subjects: 290
Study: 20921028

Group type: COMPARATOR
Intervention: Spasticity assessment at all time points (6, 12, 24, 36 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Functional recovery assessment (ARAT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contracture assessment
Number of subjects: 30
Study: 19482378

Group type: COMPARATOR
Intervention: Control group (CG): standard health intervention
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Education intervention and a program of home blood pressure monitoring (EG)
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Card control intervention and HBPM programme (CHG)
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Education intervention, card control and HBPM programme (ECHG)
Number of subjects: 1104